ReVera Secures $11.2M in Series B Funding

ReVera, a provider of advanced compositional metrology solutions for semiconductor device manufacturing, announced a second round of funding totaling $11.2 million. ATA Ventures of Redwood City, Calif. led the investment round, with original investor Crosslink Capital of San Francisco, Calif. and members of the company’s senior management also participating.

With the funding, ATA Ventures Managing Director Pete Thomas joins the ReVera Board of Directors along with Michael Stark and Dave Epstein of Crosslink Capital and Dave Perloff and Dave Ring of ReVera. Pete Thomas states: “Driven largely by the rapid growth of portable consumer semiconductor electronics, the latest semiconductor device technologies are implementing new, compositionally-critical materials and processes at an unprecedented pace. ReVera is successfully enabling the production of these new materials with their in-line compositional metrology technology and very nicely fits our investment target of companies that exhibit unusually superior technology.”

Dave Ring, CEO and President of ReVera, said: “We are delighted to have a semiconductor industry veteran and highly successful investor such as Pete Thomas of ATA Ventures join ReVera’s Board of Directors. We are also pleased by the continuing confidence shown by Crosslink Capital through their additional significant investment. We have seen rapid acceptance of our RVX1000 compositional metrology tool in leading-edge semiconductor fabs for production monitoring of advanced ultra-thin dielectric films and other processes. This round of funding will allow us to accelerate new product development and our global fan-out to additional customers and applications.”

http://www.revera.com

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.